Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd executive Nir Eran, Vice President of Operations, has reported his initial holdings as an insider. He directly holds 10,398 Ordinary Shares. He also holds options to purchase Ordinary Shares, including a grant for 22,500 shares at an exercise price of 6.1500 expiring on August 28, 2028, and additional grants for 22,500 underlying shares each at an exercise price of 7.5500 expiring on October 22, 2035, with exercise eligibility beginning on various dates between October 22, 2026 and October 22, 2029. The options are exercisable using a net-exercise method, and the exercise prices shown in U.S. dollars are convenience translations from NIS using the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd VP Quality Yael Brenner has filed an initial insider report listing her equity interests in the company. The filing shows direct ownership of 6,266 Ordinary Shares, along with several options to purchase Ordinary Shares, each for 15,000 underlying shares at exercise prices of $6.15 and $7.55 per share with expirations in 2028 and 2035. The options are exercisable using a net-exercise method, meaning only the in-the-money value is settled in shares.
Kamada Ltd executive Reshef Liron, VP Human Resources, filed an initial ownership report showing holdings of stock options on the company’s ordinary shares. The options are exercisable using a net-exercise method and their exercise prices in U.S. dollars reflect a translation from NIS as of March 13, 2026.
The holdings include option tranches for 10,000 ordinary shares at an exercise price of $5.33 per share expiring in 2029, and tranches for 15,000 ordinary shares at an exercise price of $7.55 per share expiring in 2035, all held directly.
Kamada Ltd director Karnit Goldwasser filed an initial Form 3 reporting holdings of stock options on Ordinary Shares. The filing lists several option grants with exercise prices of 7.5200 and 6.1500 per share, expiring between September 25, 2026 and June 22, 2029. Each grant covers either 6,625 or 7,500 underlying Ordinary Shares and is held directly. The options are exercisable using a net-exercise method, and the exercise prices in U.S. dollars reflect a convenience translation from NIS based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd. Chief Financial Officer Chaime Orlev has filed an initial Form 3 reporting his equity holdings in the company. He directly owns 11,633 Ordinary Shares and holds several grants of options to purchase Ordinary Shares, each covering 22,500 underlying shares at exercise prices of 6.18, 6.15 and 7.55 per share, with expirations between 2028-08-28 and 2035-10-22. The options are exercisable using a net-exercise method, and the exercise prices in U.S. dollars are convenience translations from NIS based on the Bank of Israel exchange rate as of March 13, 2026.
Kamada Ltd director Leon Recanati filed an initial ownership report showing substantial holdings in the company. He directly owns 631,143 Ordinary Shares and indirectly holds 1,455,459 Ordinary Shares through GOV Holdings and 1,346,335 Ordinary Shares through Insight. He also holds several option grants to purchase Ordinary Shares at exercise prices of $7.52 and $6.15, with expirations in 2026 and 2029. The options are exercisable using a net-exercise method, which settles only the in-the-money value in shares rather than requiring full cash payment.
KAMADA LTD vice president of US Commercial Jon Knight filed an initial ownership report showing multiple stock option holdings, rather than new trades. Each option grant covers 15,000 ordinary shares at exercise prices of $5.88 or $7.14, with expirations in 2028 and 2035. The options become exercisable on various dates between March 2023 and October 2029 and are exercisable using a net-exercise method, meaning the holder can pay the exercise price using some of the underlying shares instead of cash.
Dekel Benjamin, a director of Kamada Ltd., reported his holdings of stock options on Kamada’s ordinary shares. The filing lists four option positions, each covering 4,000 underlying ordinary shares at an exercise price of $6.2600 per share, with exercise dates on 2024-09-07, 2025-09-07, 2026-09-07, and 2027-09-07, all expiring on 2030-03-07. The options are exercisable using a net-exercise method, and the U.S. dollar exercise prices are translated from NIS using the Bank of Israel exchange rate as of March 13, 2026.
KAMADA LTD executive Livneh Nir, the company’s VP and General Counsel, filed an initial Form 3 reporting holdings of stock options on ordinary shares. The filing lists several option grants with exercise prices of 5.6200 and 7.5500, expiring between 2029-10-23 and 2035-10-22. The options, covering blocks such as 9,485, 10,000 and 15,000 underlying ordinary shares, are held directly and are exercisable using a net-exercise method.
Kamada Ltd. files its 2025 annual report, outlining its plasma-derived biopharmaceutical business, risk profile, and capital structure. As of December 31, 2025, it had 57,686,056 Ordinary Shares outstanding. Most revenue comes from its Proprietary Products segment, which supplied about 87% of total revenues in 2025.
The company is highly dependent on a few key therapies and partners. KEDRAB, GLASSIA, its CMV immune globulin product, and GLASSIA royalties together contributed roughly 59% of 2025 revenue, with about 55% of total revenues generated in the United States. Kamada receives GLASSIA royalties from Takeda at 12% of net sales through August 2025 and 6% thereafter until 2040, with a minimum of $5 million per year.
The report highlights concentration risks around Kedrion, which distributes KEDRAB in the U.S. under an agreement projecting approximately $180 million of minimum purchases over 2024–2027, and around key plasma suppliers and contract manufacturers. Kamada is investing in three U.S. plasma collection centers to secure specialty plasma and sell normal source plasma but notes execution, regulatory, and donor-availability risks.